Some new insight in a recent article in Dermatology News explains how iPLEDGE classification for transgender patients can be challenging. Some of the patient considerations include changing hormone levels and childbearing potential.
Patients who wish to take isotretinoin, one of the most common acne treatments, are subject to the requirements of the iPLEDGE Program, a federally mandated computer-based risk management program. Based on gender, it is designed to eliminate fetal exposure by isotretinoin use. The program strives to ensure that no female patient starts isotretinoin therapy if pregnant and no female patient on isotretinoin therapy becomes pregnant.
At the annual meeting of the American Academy of Dermatology, Dr. Brian Ginsburg, a New York–based dermatologist, recommended modifying patient intake forms to allow the individual to self-identify gender and respecting the use of correct pronouns preferred by patients. Additionally, having “honest conversation” with patients who were previously registered on iPLEDGE regarding their gender classification is important.
Want to learn more? The full article by Elizabeth Mechcatie can be found here: http://www.edermatologynews.com/news/conference-news/american-academy-of-dermatology-annual-meeting/single-article/aad-transgender-patients-isotretinoin-regs-can-be-a-challenge/07c8994f5b4c08df751a7c7ab5cb65c8.html
More on iPLEDGE: https://www.ipledgeprogram.com